Physiological and pathophysiological roles of NAMPT and NAD metabolism

By A. Garten, Susanne Schuster, Melanie Penke, T. Gorski, T. Giorgis, W. Kiess. Nature Reviews Endocrinology, 2015

643 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

NAD+ intermediates: The biology and therapeutic potential of NMN and NR (2017, positive): “These findings likely provide an important clue to resolve a current controversy around the pathophysiological importance of eNAMPT as a systemic NAD biosynthetic enzyme versus a proinflammatory cytokine (Garten et al., 2015; Hara et al., 2011) and also suggest that circulating dimeric eNAMPT contri”
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential (2020, background): “Supplementation of NR or NMN can protect against the decrease of NAD levels, and partially inhibit the weight gain of the mice fed with HFD by enhancing energy expenditure.(448) The NAD biosynthesis regulated by NAMPT in adipocytes plays an important role in the pathogenesis of obesity-related metab”
Therapeutic potential of NAD-boosting molecules: the in vivo evidence (2018, positive): “Additionally, increased levels of eNAMPT are seen in non-alcoholic fatty liver disease (NAFLD) (Garten et al., 2015), obesity, diabetes mellitus type 2 (T2DM), cardiovascular disease (Chang et al., 2011; Chen et al., 2006; Haider et al., 2006; Saddi-Rosa et al., 2013), and cancer (Audrito et al.,…”